[Fetal outcome after cervical ripeness-adjusted labor induction with prostaglandin E2 in relation to cervix status. Results of a multicenter study].
Prostaglandin E2 is often used for induction of labour. A procedure appropriate for obstetrical condition of the cervix uteri is recommended. 1,472 births with a medical indication were induced in a multicenter-study. With a bishopscore < 5 prostaglandin E2 gel intracervical and with a score between 5 and 8 vaginal tablets were used for induction. Appropriate for the condition of cervix it was allowed to continue the induction. With a bishopscore > 8 an infusion of oxytocin was given. The fetal outcome was evaluated appropriate for the condition of cervix before and during induction of labour. The APGAR-score one minute post partum was < 8 in 10.8 per cent of all neonates. This part was near the same in the gel- and in the tablet group (p > 5%). By continuation of induction, the part with pathological findings was at all times not in relation to the different groups of cervical condition. It's the same by APGAR-scores 5 and 10 minutes after delivery. The acidotic morbidity at all was 10.7%. Also in this connection it was only an unimportant (p > 5%) increasing to observe then the induction was continued. There is no relation between the different groups of cervical condition and the acidotic morbidity. Under observation of mother and child the to cervical condition appropriated used method of induction of labour does not expect a bad neonatal outcome. The longer the cervix is unripen, the higher is the rate of delivery by caesarean section. The exploitation of the possibilities of induction by drugs can be recommended.
Bredow
V
V
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Medizinischen Fakultät, Ernst-Moritz-Arndt-Universität Greifswald.
Straube
W
W
D000136:Acid-Base Equilibrium / Q000187:drug effects; D000282:Administration, Intravaginal; D001034:Apgar Score; D002584:Cervix Uteri / Q000187:drug effects*; D002585:Cesarean Section; D015232:Dinoprostone / Q000008:administration & dosage*; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D007751:Labor, Induced / Q000379:methods*; D010121:Oxytocin / Q000008:administration & dosage; D011247:Pregnancy; D011256:Pregnancy Outcome; D011273:Pregnancy, Prolonged
D010121:Oxytocin; D015232:Dinoprostone
Das fetal outcome nach zervixbefundorientierter differenzierter Geburtseinleitung mit Prostaglandin E2 in Beziehung zum Zervixstatus. Ergebnisse einer Multizenterstudie.